MADISON, N.J. /eNewsChannels/ — NEWS Apr 19, 2013: Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.
Archive | News: Pharma RSS feed for this section
Paragon BioTeck and Bausch + Lomb sign Exclusive License Agreement for Phenylephrine
RXCut Plus announces new website designed to help people get the best prescription drug prices
DOVER, Pa. /eNewsChannels/ — RXCut(R) Plus announced this week a new website that is designed to help people get the best prescription price available. ‘Our cutting-edge pharmacy price search is tightly integrated with Google Maps technology making it faster and easier for people to access pharmacy information,’ Gerard Ferro, founder and CEO RXCut(R) Plus, says.
New products featured in Laboratory Supply Distributors’ latest catalog serve chromatography, biotechnology, pharma markets
MILLVILLE, N.J. /eNewsChannels/ — Laboratory Supply Distributors Corp., a provider of diverse products for the chromatography, biotechnology, pharmaceutical and environmental industries, today announced the launch of its 2013 catalog. It showcases many new products for the life science and biotech markets.
Make 2013 a Year Without Head Lice!
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give [...]
Make 2013 a Year Without Head Lice!
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give [...]
Make 2013 a Year Without Head Lice!
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give [...]
Make 2013 a Year Without Head Lice!
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give [...]
Make 2013 a Year Without Head Lice!
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give [...]
Facts of Lice: Head Lice Spread Fast, So Prevention is Key, says George Coleman, founder and president of Connecticut’s Dermedics Laboratories
BRIDGEPORT, Conn. /eNewsChannels/ — October is the month the kids begin to scratch, says George Coleman, founder and president of Connecticut’s Dermedics Laboratories. That’s because the start of a new school year has children literally putting their heads together – and that’s how head lice infestations get started.
Marketing Research Company CMI adds Paul Gondek Ph.D to Healthcare Solutions Practice
ATLANTA, Ga. /eNewsChannels/ — Paul Gondek has joined CMI to expand the company’s Healthcare Solutions practice to support healthcare, pharmaceutical, and medical device companies. As vice president client solutions and healthcare lead, Gondek will further enhance an experienced pharmaceutical team, using advanced analytics and immersive techniques to provide strategic insights that brand teams can use.
CMI’s Mike Mabey to Co-Present with Pfizer Specialty at 2012 PMRG Annual National Conference
ATLANTA, Ga. /eNewsChannels/ — CMI’s Mike Mabey, vice president, client solutions, and Jarod Ricci, senior manager, market analytics, Pfizer (NYSE:PFE), will present ‘Using Information-Seeking Behavior to Drive Segment-Specific Communication Strategies’ at the 2012 PMRG (Pharmaceutical Marketing Research Group) Annual National Conference.
E’shee Clinical Esthetic announce Elixir of Life KI Therapy Serum
PHILADELPHIA, Pa. /eNewsChannels/ — E’shee Clinical Esthetic announced this week a new addition to its product line of skin serums – Elixir of Life KI Therapy Serum – designed to deliver ultimate skin rejuvenation.
Highland Ophthalmology Associates Offers ProKera to Corneal Patients
NEW WINDSOR, N.Y. /eNewsChannels/ — Mary Davidian, M.D., of Highland Ophthalmology Associates, a leading eye surgeon in The Hudson Valley, announces offering her patients a unique corneal wound repair and healing device called ProKera(R). Today, ProKera(R) is the only medical device that can provide wound healing to patients afflicted with a damaged cornea, the outer transparent surface of the eye.
Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy
AUSTIN, Texas /eNewsChannels/ — Bio-Medical Services has received USDA approval and is now offering ACTT(TM) – allergy drop immunotherapy – as an alternative method for administering allergy treatment for pet allergy patients. An in-house pilot study is now underway, and preliminary findings are expected in the Fall of 2012.
Reaction Biology today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain
MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.
Soy Labs, LLC and the Missouri Plant Science Center to spur innovation and economic development in Missouri
MEXICO, Mo. /eNewsChannels/ — Missouri Gov. Jay Nixon, whose job-creation strategy has focused on investing in science, technology and innovation, and encouraging and incentivizing entrepreneurship, selected Soy Labs and the Missouri Plant Science Center on Friday, as the site to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act.
E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream
PHILADELPHIA, Pa. /eNewsChannels/ — E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream – an amazingly powerful skin anti-oxidant. This supremely elegant formula combines the finest bioengineering technologies.
City of Scranton, Pa., selects Millennium Administrators, Inc. to Provide Benefit Administration for Active Fire and Police
SCHWENKSVILLE, Pa. /eNewsChannels/ — Millennium Administrators, Inc., a benefits administrator, has signed a contract with the City of Scranton to provide benefit administration services for over 500 city employees. Millennium is providing administrative oversight for the city benefit program, including cost containment initiatives, claim audits and administrative services
ProtiLife Distribution Inc. Launches Health-Focused Online Weight Loss Program for American Women
MONTREAL, Quebec /eNewsChannels/ — ProtiLife Distribution Inc., a leader in the development and distribution of high-quality protein supplements for over 20 years, has launched its online weight loss program to the U.S. market.
Multi-Tier Micro Plate System announced by Laboratory Supply Distributors Corp.
VINELAND, N.J. /eNewsChannels/ — Designed for analytical research and clinical diagnostic testing, Laboratory Supply Distributors Corp. announces the 96-Well Multi-Tier™ Micro Plate System. Its unique, patented design allows for more flexibility and ease of use.
REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
SAN MARINO, Calif. /eNewsChannels/ — Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
New Strategies and Business & Decision Partner to Bring Industry Leading ERP Solutions to Pharma Industry
PHOENIX, Ariz. /eNewsChannels/ — As a part of Business & Decision’s ongoing focus in the Life Science market, we are delighted to announce a partnership with New Strategies, the creators of ‘AX for Pharma’ an industry leading Enterprise Resource Planning solution for the Pharmaceutical industry. This solution, which is based on Microsoft Dynamics AX, has been designed to address the primary business process needs of a Life Science / Pharmaceutical organization.
Ethnographer Laura Winn Johnson to Present at PMRG Institute
ATLANTA, Ga. /eNewsChannels/ — CMI, a full-service marketing research company, has been chosen for the second consecutive year to present a session at The Fourth Annual Meeting of the PMRG Institute in Boston, Mass., on Oct. 24-26, 2010. The theme for this year’s conference is ‘Navigating Healthcare’s Shifting Currents: Essential Techniques for the Healthcare Marketing Researcher.’
Reaction Bio Receives National Cancer Institute Grant for Epigenetic Platform
MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.
Epeius Bio’s Rexin-G® Receives High-tech Validation as Strategic Anti-cancer Agent
SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime [...]
BIO Investor Forum: Epeius Biotechnologies Investment Opportunity
SAN FRANCISCO, Calif. — Epeius Biotechnologies Corporation (www.epeiusbiotech.com), an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San [...]
Epeius Biotech Reports Dose-Dependent Efficacy and Survival Benefits, Efficacy of Rexin-G in Metastatic Pancreas Cancer
SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, which [...]
Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy
SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G® has once again accomplished what standard cancer treatments and [...]
Whistleblower Mark Whitacre says ‘The Informant’ Movie is Only Part of the Story
NEW YORK CITY, N.Y. — As Mark Whitacre, COO of Cypress Systems, Inc., walked the red carpet on September 15 during the premiere of “The Informant,” he had something to say: he is NOT the same man who blew the whistle on his employer in the early 1990′s, putting him in the spotlight of one [...]
Pharmaceutical eMarketing using Social Media: How to Use It Effectively
NEW YORK, N.Y. — Eularis is announcing the release of its report “How To Harness The Power Of Social Media In Pharmaceutical eMarketing.” This report puts to rest the issues around “can’t,” and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives. “I see this common belief that [...]
Patented Green Technology is Potential Silver Bullet for Swine Flu and Most Common Infections
FORT LAUDERDALE, Fla. — Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in the U.S. [...]
Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results [...]
Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate [...]
The World’s Smallest Hero! Epeius Bio’s Rexin-G, Targeted Therapy for Metastatic Cancers
SAN MARINO, Calif. — Epeius Biotechnologies’ Rexin-G® is the world’s smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high [...]
Eularis Releases Comprehensive Report on Effective Pharmaceutical eMarketing
NEW YORK, N.Y. — Eularis is announcing the release of an update to its report “Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web 2.0 and Beyond.” The comprehensive report has been created to demystify the world of eMarketing and Social Media to provide Pharmaceutical marketers with a competitive edge and the latest information on [...]
Eularis to Hold Pharma Marketing ROI MasterClass in London
LONDON, U.K. — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing budgets often represent a major portion of a company’s cost [...]
Epeius’ Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is [...]
Hot Rising Fitness Star Natalie Waples Takes On Steroids Issue in Fitness Biz
ORLANDO, Fla. — Natalie Waples is one of the brightest young stars in the fitness firmament. The eye-catching Canadian made her pro debut last season, winning her first professional event at the IFBB North American Figure Championships. She has graced the September ’08 cover of Inside Fitness Magazine and her new DVD, “Building a Beautiful [...]
Cancer-Destroying Biotech: Epeius Bio Launches Rexin-G eBook Tutorial
SAN MARINO, Calif. — Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated [...]
Epeius Bio’s Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemo-Resistant Pancreatic Cancer
SAN MARINO, Calif. — Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, [...]
Silver Safety Committee Gives Guidelines for Safe Use of Any Ionic or Colloidal Silver Supplement
FORT LAUDERDALE, Fla. — The Silver Safety Committee this week announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver. The Silver Safety Committee consists of doctors, chemistry professors and [...]
Epeius Bio Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well [...]
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Cancers
SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G [...]
Eularis Analyzes Pre-Launch Brand Planning with New Pharma Industry Report
LONDON, U.K. — In today’s environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits – until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. [...]
Rexin-G Clinical Trials for Pancreatic Cancer and Breast Cancer Open in New York
SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. [...]
SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)
FRESNO, Calif. — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at cypsystems.com [...]
Epeius Biotechnologies Reveals a New Generation of Tools for Medical Gene Delivery
SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled “Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ,” was published in the October issue of [...]
Eularis Releases First-Ever Pharma Study: ROI of Pre-Launch Named Patient Programs
NEW YORK, N.Y. and LONDON, U.K. — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, “Implementing a pre-launch named patient programme – evidence of increased market share,” provides pharmaceutical companies with insight and mathematical justification into the cash [...]
Epeius Biotechnologies Rexin-G® for Metastatic Cancer Highlighted by National Cancer Institute Journal
SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine [...]
Eularis Analyzes Most Effective Generics Defense Strategies with New Pharma Industry Report
NEW YORK, N.Y. and TOKYO, JAPAN — Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company profits. In the United States, the Generics Industry claims more [...]
Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit [...]
Eularis Challenges Pharma Industry in 2008: Are You Measuring the Wrong Things
LONDON UK, and TOKYO Japan — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years. [...]
Intravenous Infusions of Epeius Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity
SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007). In this [...]
OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies
RICHMOND, Texas — CYNACON / OCuSOFT (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to announce that as a convenience to all patients, OCuSOFT(R) Lid Scrub(TM) Plus is now available in CVS pharmacies, nationwide. OCuSOFT(R), Inc., recognized as the market leader, recently introduced OCuSOFT(R) Lid Scrub(TM) [...]
Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes
SAN MARINO, Calif. — ASCO 2008 — Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G followed by Reximmune-C-for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J Clin Oncol 26:3077, 2008). Rexin-G and Reximmune-C are pathotropic (disease-seeking) [...]
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity
SAN MARINO, Calif. — Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, [...]
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the [...]
Eularis to Address Marketing Return at Japanese Pharma Marketing Excellence Conference
TOKYO and LONDON, UK — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan. At 11:45 a.m. on Monday, 19 May 2008, Dr. [...]
Dr. Andree Bates to Address Pharma Research ROI
NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation titled, “How to Tell if You Are Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return.”
-
SecuGen Corporation announces the establishment of SecuGen India to address growing market for fingerprint biometrics
-
Calif. Gov. Brown announces appointments to California Superior Courts for May 21, 2013
-
Calif. Gov. Brown Announces Appointments for May 21, 2013 to 30th District Agricultural Association
-
Huskies for Adoption Memorial Day Event in Hermosa Beach hosted by Husky Haven of LA
-
John Krause seeking 2014 Republican Nomination to represent Florida’s First Congressional District
-
Edgewood Partners Insurance Center Videos help companies to better understand and manage benefits and key healthcare changes
-
Bill to Protect Local Calif. Governments from Dog Park Liability Passes Assembly
-
San Francisco International Airport (SFO) Ten-Year Capital Improvement Plan announced by SF Mayor Lee
-
Dance Prodigy and TV star from ‘Dance Moms’ Sophia Lucia will Attempt to Break Guinness World Record
-
The National Inclusion Project, co-founded by entertainer Clay Aiken, announces it is recipient of JL Simmons NonProfit PR Grant
-
Could National ‘Snow Gratitude’ Ceremonies Extend Future of SnowSports?
-
Calif. Assemblyman Gatto’s Resolution to Overturn Citizens United Decision Passes First Major Legislative Hurdle
-
Neotrope to assist Food Finders Inc to Redistribute Food Donated by California Hospitality Industry and Local Grocers to Fight Hunger
-
US Secretary of State John Kerry announces Ira Forman will serve as the Special Envoy to Monitor and Combat Anti-Semitism
-
Viet Nam veteran and citizen tax reform advocate, John C. Garrison, decries IRS denial of U.S. Workers’ deduction of living expense
-
San Francisco’s First New Fire Station in More Than 40 Years to Meet Safety Needs of Vibrant, Growing Neighborhood
-
Sarah: Who is Kerry going to appoint to combat the worldw...
-
neotrope: We're very pleased to help this great nonprofit i...
-
april: This is wonderful news! Congratulations to the Nat...
-
Linda Davidson: I will pass on and encourage people to "Thank Mot...
-
-
Michael Farris: The process for proposing and ratifying a constitu...
-
Devany: In order to enforce a judgment against you the she...
-
college textbooks: It's a huge contribution indeed! The book written...
- Advertisement -
Hormone Therapy and Breast Cancer: Is There a Connection? ask Practitioners from Belvidere Pharmacy and Balancing Health
SOMERSET, N.J. /eNewsChannels/ — From the blogosphere to mainstream media, there’s been a recent-and disturbing-buzz on a connection between hormone replacement therapy and a higher risk for advanced-stage breast cancer in post-menopausal women. The recent media focus stems from a study published in the Oct. 2010 issue of the Journal of the American Medical Association. Practitioners from Belvidere Pharmacy and Balancing Health, both experts in women’s health, examine the issue.